University of Texas Health Science Center at Houston, McGovern Medical School, Department of Psychiatry and Behavioral Sciences, Houston, TX 77054, United States.
University of Texas Health Science Center at Houston, McGovern Medical School, Department of Psychiatry and Behavioral Sciences, Houston, TX 77054, United States.
Psychiatry Res Neuroimaging. 2018 Aug 30;278:13-20. doi: 10.1016/j.pscychresns.2018.06.005. Epub 2018 Jun 12.
The neural mechanisms underlying the therapeutic effects of lamotrigine in bipolar depression are still unexplored. This preliminary study compares the effects of a 12-week treatment with lamotrigine on brain volumes in adults with bipolar disorder (BD).12 BD type II patients (age: 49.33 ± 9.95 years, 3 males, 9 females) and 12 age and gender-matched healthy controls (HC) (HC; age: 41 ± 8.60 years, 3 males, 9 females). BD patients were initially administered 25 mg/day of lamotrigine, which was progressively escalated to 200 mg/d. BD participants underwent brain imaging prior to and following lamotrigine treatment. A 50% reduction in depressive scores indicated "remission". Bayesian general linear models controlled for age, gender and intracranial volume were used to examine changes in relevant brain region following treatment. A posterior probability > 0.90 indicated evidence that there was an effect of diagnosis or remission on brain volumes. Probability distributions of interaction effects between remission and time indicated that BD responders displayed decreased amygdala, cerebellum and nucleus accumbens volumes following lamotrigine treatment. No serious adverse side effects were reported. The antidepressant effects of lamotrigine may be linked to volumetric changes in brain regions involved in mood and emotional regulation. These findings are preliminary and replication in a larger sample is warranted.
拉莫三嗪在双相情感障碍中的治疗作用的神经机制仍未被探索。本初步研究比较了双相情感障碍(BD)成人接受为期 12 周的拉莫三嗪治疗对脑体积的影响。12 名 BD Ⅱ型患者(年龄:49.33 ± 9.95 岁,3 名男性,9 名女性)和 12 名年龄和性别匹配的健康对照组(HC)(HC;年龄:41 ± 8.60 岁,3 名男性,9 名女性)。BD 患者最初服用 25mg/天的拉莫三嗪,逐渐增至 200mg/d。BD 患者在接受拉莫三嗪治疗前后进行脑部成像。抑郁评分降低 50%表明“缓解”。贝叶斯广义线性模型控制年龄、性别和颅内体积,用于检查治疗后相关脑区的变化。后验概率>0.90 表明存在诊断或缓解对脑体积的影响的证据。缓解和时间之间交互效应的概率分布表明,拉莫三嗪治疗后,BD 应答者的杏仁核、小脑和伏隔核体积减小。未报告严重不良反应。拉莫三嗪的抗抑郁作用可能与参与情绪和情感调节的脑区的体积变化有关。这些发现是初步的,需要在更大的样本中进行复制。